A moderate 500-m treadmill walk for estimating peak oxygen uptake in men with NYHA class I-II heart failure and reduced left ventricular ejection fraction by Mazzoni, G et al.
RESEARCH ARTICLE Open Access
A moderate 500-m treadmill walk for
estimating peak oxygen uptake in men
with NYHA class I-II heart failure and
reduced left ventricular ejection fraction
Gianni Mazzoni1,2, Biagio Sassone3, Giovanni Pasanisi4, Jonathan Myers5,6, Simona Mandini7* , Stefano Volpato8,
Francesco Conconi7, Giorgio Chiaranda9 and Giovanni Grazzi1,2
Abstract
Background: Maximal cardiopulmonary exercise testing (CPX) is the gold-standard for cardiorespiratory fitness
assessment in chronic heart failure (CHF) patients. However, high costs, required medical supervision, and safety
concerns make maximal exercise testing impractical for evaluating mobility-impaired adults. Thus, several
submaximal walking protocols have been developed and currently used to estimate peak oxygen consumption
(VO2peak) in CHF patients. However, these tests have to be performed at close to maximum exercise intensity. The
aim of this study was to examine the validity of a 500-m treadmill-walking test carried out at moderate intensity for
estimating VO2peak in community-dwelling adult and elderly patients with CHF and reduced left ventricular
ejection fraction (HFrEF).
Methods: Forty-three clinically stable men with HFrEF (age 67.7 ± 9.2 years, and left ventricular ejection fraction,
LVEF 38% ± 6%) underwent exercise testing during an outpatient cardiac rehabilitation/secondary prevention
program. Each patients completed a CPX, and a moderate and self-paced (11–13/20 on the Borg scale) 500-m
treadmill-walking test. Age, weight, height, walk time, and heart rate during the 500-m test were entered into
prediction equations previously validated for VO2peak estimation from a 1000-m walking test in patients with
cardiovascular disease and preserved LVEF.
Results: Directly measured and estimated VO2peak values were not different (21.6 ± 4.9 vs 21.7 ± 4.6 mL/kg/min). The
comparison between measured and estimated VO2peak values yielded a correlation of R = 0.97 (SEE = 0.7 mL/kg/min,
P < 0.0001). The slope and the intercept coincided with the line of identity (Passing and Bablock analysis, P = 0.50).
Residuals were normally distributed, and the examination of the Bland-Altman analysis do not show systematic or
proportional error.
Conclusions: A moderate and self-regulated 500-m treadmill-walking test is a valid tool for VO2peak estimation in
patients with HFrEF. These findings may have practical implications in the context of transitioning from clinically based
programs to fitness facilities or self-guided exercise programs in adults and elderly men with HFrEF.
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Background
Chronic heart failure (CHF) is an increasingly important
health problem because of the aging population, im-
proved survival rate after acute cardiovascular events,
and the escalating costs attributable to symptoms and
associated repeated hospitalizations, despite optimal
medical therapy [1]. Cardiorespiratory fitness (CRF),
usually best reflected by peak exercise oxygen consump-
tion (VO2peak), has been shown to be a powerful and
independent prognostic marker in patients with CHF
[2, 3], and is strongly related to walking speed [4, 5].
Walking tests of varying distance and times are com-
monly used to assess exercise tolerance in various clin-
ical conditions (including CHF). These tests have to be
performed at an intensity close to maximum. In fact, the
participants are instructed to “cover as much ground as
you possibly can” during a certain time [6] or “to walk as
fast as possible” for a certain distance [7, 8].
However, daily activities rarely require maximal effort,
and thus the ability to perform sustained submaximal exer-
cise is an important component of health-related fitness as-
sessment. In this respect, examination of submaximal
exercise capacity can be useful not only to functionally
evaluate patients but also for developing appropriate exer-
cise prescriptions, adjusting the medical regimen, and iden-
tifying the need for further diagnostic interventions [9].
Submaximal walking tests for CRF assessment may be
useful for measuring improvements not captured by
VO2peak such as the capacity to perform activities of
daily living, particularly for populations whose health
limits their ability to exercise at maximal effort [10].
Slow walking in older adults reflects disease severity and
underlying frailty, and has significant consequences for
the individual, and the public health system [11]. In
addition, the need of using simple exercise tests to im-
prove the admission on cardiac rehabilitation/secondary
prevention programs has been recently emphasized, par-
ticularly for low-resource settings [12].
The moderate speed maintained during a 1-km tread-
mill walk (1 k-TWT) has been demonstrated to be a valid
and simple tool for CRF estimation [13, 14], and is in-
versely related to survival [15, 16], and hospitalization [17]
in outpatients with cardiovascular disease (CVD) and pre-
served left ventricular ejection fraction (LVEF). However,
the 1 k-TWT can be time-consuming, particularly when
performed by functionally limited patients. A shorter test
providing similar functional information while limiting
physical demands of patients and taking less time could
be valuable. Thus, the aim of this study was to examine
the validity of a 500-m treadmill-walking test carried out
at moderate intensity for estimating peak oxygen con-
sumption (VO2peak) in community-dwelling adult and
elderly patients with CHF and reduced left ventricular
ejection fraction (HFrEF).
Methods
Participants
43 consecutive medically stable male outpatients with
HFrEF (LVEF ≤45%), aged 35 to 83 yrs. (67% over
65 yrs), classified as NYHA class I-II are included in the
study. Each subject completed a clinical evaluation in-
cluding personal and family history and a medical exam-
ination. Left ventricular ejection fraction was derived
from recent echocardiographic evaluation. Standard
blood chemistry analyses previously performed were re-
corded. Weight and height were measured and used to
calculate body mass index (BMI). Blood pressure (BP)
was measured, and hypertension was defined as systolic
BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg, or use of anti-
hypertensive agents. All patients performed a maximal
cardiopulmonary exercise test (CPX) for direct VO2peak
determination, and a 500-m moderate treadmill-walking
test for VO2peak estimation. Patients were instructed
not to change dietary habits, not to consume any food
or beverages except water for ≥2 h before testing, and
not to engage in any type of physical activity for two
days before testing. All were evaluated while receiving
their usual medications and were on a stable medical
regimen for at least three months before testing. 37
(86%) subjects were receiving β-blockers as follows: biso-
prolol (n = 19, 6 ± 3 mg/d), carvedilol (n = 11, 31 ±
19 mg/d), and metoprolol (n = 7, 135 ± 42 mg/d).
Exercise testing procedures
Cardiopulmonary exercise testing
VO2peak was determined using a treadmill ramp proto-
col beginning at speed of 1.5 mph (2.4 km/h) and 1.5%
grade with subsequent increments of 0.1 mph and 0.5%
grade every thirty seconds [18]. Patients performed the
maximal test until subjective exhaustion, exertional
chest pain or other untoward findings that would neces-
sitate termination. Exercise was considered adequate if it
was limited by dyspnea or muscle fatigue (Rate of per-
ceived exertion, RPE ≥ 18/20), and by the attainment of
at least two of the three following criteria: heart rate
value ≥85% of the age-predicted maximum, VO2 plateau
approaching maximal exertion, and a respiratory ex-
change ratio ≥ 1.05 [19, 20]. Tight gripping of the hand-
rails was not permitted; finger or palm placement on the
handrails was allowed for balance only when necessary.
Standard 12-lead electrocardiograms were continuously
monitored and recorded during the test (Quark T12x,
Cosmed, Rome, Italy). Gas-exchange measurements
were performed using a metabolic cart (Omnia 1.5,
Cosmed, Rome, Italy). Calibration of the system was per-
formed before each test using a three-liter syringe to
calibrate the flowmeter and by using gases with known
oxygen, carbon dioxide and nitrogen concentrations to
calibrate the gas analyzers. VO2 and carbon dioxide
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output were acquired breath-by-breath and averaged
over 15 s intervals. VO2peak was defined as the highest
level of VO2 achieved during the test.
500-m treadmill-walking test
Within one week from the CPX, each patient performed
a 500-m treadmill-walking test. Each patients were in-
formed to adopt a comfortable walking pace sustainable
for 10 to 20 min. Participants were educated to maintain
a moderate perceived exercise intensity using the Borg
6–20 scale. The test was performed on the level, and
began with a preliminary phase at 2.0 km/h, with subse-
quent increases of 0.3 km/h every 30 s up to a walking
speed corresponding to a perceived exertion of 11–13
on the Borg scale. The 500-m walk was then started and
the rate of perceived exertion acquired every 2 min.
Walking speed was adjusted by the operator following
the patient’s perceived intensity. In this way, the exercise
intensity was individualized and maintained at moderate
perceived exertion.
Heart rate was monitored continuously during the test
using a Polar RS100 heart rate monitor (Polar Electro,
Kempele, Finland). Blood pressure was monitored before
and immediately after the test. Heart rate was averaged
every five seconds and mean and maximal values during
the test were determined. Age, height, weight, time to
walk 500-m multiplied by two, and heart rate were en-
tered into the equations developed to estimate VO2peak
by the 1 k-TWT [13]. The two equations were deter-
mined using a multivariate forward stepwise regression
procedure [13]. A coefficient of determination was cal-
culated for each variable for the VO2peak estimation.
After removal of variables that were not significant, the
model included age, BMI, walking speed and heart rate.
The model was set as follows:
Y ¼ β0–β1X1–β2X2–β3X3–β4X4
where Y = directly measured VO2peak; β = regression co-
efficient for each of the independent variables; X1 =
mean walking speed in km/h; X2 = BMI in weight/
height2; X3 = age in years; and X4 = higher heart rate in
beats per minute (bpm). The resulting predictive
equations were:
33:42þ 2:79 walking speedð Þ–0:49 BMIð Þ–0:14 ageð Þ½ 
and
46:11þ 4:41 walking speedð Þ–0:40 BMIð Þ–0:30 ageð Þ–0:11 heart rateð Þ½ 
for patients taking and not taking β-blockers,
respectively.
Data analysis
Normal distribution of collected data has been verified
by using D’Agostino Pearson test. Therefore, the predict-
ing equations previously developed and validated [13]
were applied using Pearson product moment correla-
tions, SEE and paired t-test for comparison of measured
and predicted VO2peak. Passing and Bablok regression
analysis was used to determine the relationship between
measured and predicted values. Agreement between
methods has been assessed calculating the Concordance
Correlation Coefficient. Appropriateness of the model
was assessed using Bland-Altman analysis and normal
probability plots of the residuals. The level of statistical
significance was set at P < 0.05. Statistical analyses were
performed using the package Medcalc 16.2 software
(Ostende, Belgium).
Results
Both the CPX and the 500-m treadmill-walking tests
were completed by all subjects without complications.
Three subjects did not satisfy the criteria for adequate
effort. One patient interrupted the test prematurely
because of mask intolerance (i.e. claustrophobic). The
analysis thus included the results of 39 subjects. De-
scriptive characteristics of the study population are
presented in Table 1. CPX test results are presented
in Additional file 1: Table S1.
Average walking speed during the 500-m treadmill-
walking test was 4.37 ± 1.08 km/h. Mean heart rate was
90 ± 21 bpm, representing 59% ± 14% of the age-
predicted maximal heart rate (based on 220-age).
VO2peak values measured by CPX and predicted
from the 500-m treadmill-walking test resulted 21.6 ±
4.9 mL/kg/min and 21.7 ± 4.6 mL/kg/min respectively
(t = 0.9, P = 0.37). 500-m test results are presented in
Table 2.
The correlation coefficient between measured and pre-
dicted VO2peak was 0.97 (P < 0.0001), and the SEE was 0.
7 mL/kg/min. The slope and the intercept of the relation-
ship between measured and predicted VO2peak were not
significantly different from the line of identity (Passing
and Bablock analysis, P = 0.50, Fig. 1). The Concord-
ance Correlation Coefficient resulted 0.97. Residuals
were normally distributed with a mean residual value
of − 0.1 mL/kg/min. Examination of the Bland-Altman
analysis do not show systematic or proportional error
(Fig. 2).
Discussion
The major finding of this study was the VO2peak pre-
diction by a 500-m treadmill-walking test carried out
at moderate intensity in subjects with HFrEF. Pre-
dicted VO2peak strongly paralleled VO2peak mea-
sured directly by CPX. This was supported by the
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high correlation and concordance coefficients, and by
the small SEE (0.7 mL/kg/min). These findings sug-
gest that the equations validated for predicting
VO2peak using a 1000-m moderate treadmill walk in
outpatients with CVD and preserved ejection fraction,
are similarly appropriate for predicting VO2peak when
using a 500-m moderate treadmill walk in CHF out-
patients with mild to moderately reduced ejection
fraction.
These results are in agreement with those obtained by
others that have attempted to predict VO2peak using sub-
maximal walking protocols, mainly in healthy subjects and
in patients with CVD and preserved LVEF [5, 7, 21–24].
In our study, by using population specific-equations
developed for men with CVD and preserved LVEF,
VO2peak was accurately estimated in adults and elderly
subjects with HFrEF by performing a 500-m moderate
walk. In addition, the relationship between moderate
and perceptually regulated walking and cardiorespiratory
fitness in CHF outpatients has not been determined in
previous studies. Correlation coefficients observed in
our original study [13] and the present results further
support the strong association between walking speed
and peak VO2 [4].
The 500-m treadmill-walking test relies on the fa-
miliar task of moderate walking, which is the most
common activity engaged in by adults. In particular,
older adults reported that walking was their preferred
form of exercise [25, 26]. The habitual nature of
walking reduces the possibility that lack of familiarity
with the task reduces the predictive accuracy of the
results. This characteristic may also make the 500-m
walking test particularly appropriate for less fit pa-
tients or for those whom walking is their preferred
Table 1 Descriptive characteristics of the participants
n 39
Age (y) 67.7 (9.2)
Body mass index (kg/m2) 28.8 (3.8)
Left ventricular ejection fraction (%) 38 (6)
Ischemic etiology (%) 72
NYHA functional class I/II (%) 62/38
Serum sodium (mEq/L) 140 (2)
Cardiovascular risk factors
Family history of CVD (%) 66
Hypertension (%) 72
Fasting glucose (mg/dl) 105 (25)
Total cholesterol (mg/dl) 167 (47)
HDL cholesterol (mg/dl) 42 (9)
Triglycerides (mg/dl) 107 (52)
Serum creatinine (mg/dl) 1.03 (0.2)
Current smoking (%) 6
Medical history (%)
Coronary artery by-pass graft 41
Myocardial infarction 39
PTCA 30
Valvular repair/replacement 11
Other 8
Medications (%)
ACE inhibitor or ARB 89
Aspirin 80
β-blockers 89
Calcium antagonists 14
Diuretics 81
Statins 75
Data are presented as mean (standard deviation) or percentage. ACE angiotensin-
converting enzyme, ARB angiotensin receptor blocker, CVD cardiovascular
disease, NYHA New York Heart Association, PTCA Percutaneous Transluminal
Coronary Angioplasty
Table 2 500-m treadmill walking test results
Variable Mean (SD)
Exercise time (min:sec) 6:51 (2:24)
Mean walking speed (km/h) 4.37 (1.08)
Highest walking speed (km/h) 4.54 (1.06)
Mean heart rate (bpm) 90 (21)
Highest heart rate (bpm) 94 (17)
Estimated VO2peak (mL/kg/min) 21.7 (4.7)
Data are presented as mean (standard deviation)
Fig. 1 Regression of the VO2peak estimated from 500-m moderate
treadmill-walking test on the measured VO2peak (y = 2,37 + 0,90×).
The diagonal line represents the line of perfect agreement (line of
identity), and the dotted lines represent confidence interval lines
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form of physical activity. This reduces the influence
that lack of familiarity with the task might have on
the accuracy of the test. Various walking tests have
also been proposed as functional tools s for patients
with CHF; thus, we felt that a submaximal test such
as the 500-m treadmill-walking test would be valuable
in this population, particularly for low-resource
settings [12].
An advantage of the 500-m treadmill-walking test
is the fact that it is performed at an individualized
and patient-determined moderate intensity (11 to 13
on the RPE scale). This was confirmed by the aver-
age 59% of the age-predicted maximal heart rate
value in the present study, which falls within current
recommended limits (55% to 69%) for moderate in-
tensity [27]. Moreover, the average heart rate during
the 500-m test was close and well correlated with
the heart rate value at ventilatory threshold during CPX
(90 ± 21 bpm vs 93 ± 16 bpm, R = 0.83, P < 0.0001).
As such, the test may also serve as a learning trial for
proper intensity for an exercise prescription. In fact, the
exercise intensity at an RPE value between 11 and 13/20
has been associated with the lactate threshold, independ-
ent of training state [28]. Aerobic conditioning at such
an intensity has been demonstrated to be safe and opti-
mal to enhance cardiorespiratory function in patients
with chronic disease [28].
The 500-m treadmill-walking test is a simple test that
could be applied to stable mild-to-moderate CHF sub-
jects, accurately reflecting activities of daily living. The
current results provide insights into the underlying char-
acteristics and treatment of CHF patients with reduced
left ventricular ejection fraction, which may be useful to
help quantify CRF improvement or deterioration.
Study limitations
First, the small number of patients is a limit of this
study. Second, our study comprised male participants
only: thus, the results may not be generalizable to
women. Third, participants were in the mid-range of
reduced LVEF, and therefore the results may not
apply to patients with more impaired ventricular
function. Fourth, these results were obtained from pa-
tients with an interest in participating in an exercise-
based secondary prevention program. Finally, reprodu-
cibility was not assessed in this study. However, we
previously demonstrated good cross-validation and re-
producibility among cardiac outpatients performing
the test over the 1000-m distance [13]. Therefore, ex-
ternal validation of our findings is needed. In particu-
lar, future work should focus on the application of
the protocol to women with CVD and to subjects
with more impaired CRF, as well as to examine the
prognostic value of the 500-m moderate walking test,
including the determination of clinically meaningful
cut-points.
Conclusions
In outpatients with mild-to-moderate CHF, the deter-
mination of submaximal exercise capacity by a moderate
and perceptually-regulated the 500-m treadmill-walking
test, accurately predicts VO2peak. Since it is important
to document functional capacity in heart failure patients
over time, the 500-m treadmill-walking test represents a
Fig. 2 Difference compared to the mean of VO2 measured by CPX and estimated from 500-m walk (Bland and Altman plot)
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simple and potentially useful tool in the serial evaluation
of clinical status or the response to therapeutic interven-
tions including exercise prescription. While the CPX re-
mains the gold-standard for cardiorespiratory fitness
assessment in chronic heart failure patients, the 500-m
walking test may also provide an inexpensive screening
tool in this and other patient groups in which it has
been validated.
Additional file
Additional file 1: Table S1. Cardiopulmonary exercise test results.
(DOCX 16 kb)
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